Search Bar & Filters
Found 33 Actively Recruiting clinical trials
Actively Recruiting
This research aims to collect and evaluate safety and effectiveness information about Jyseleca tablet Filgotinib Maleate 100 mg and 200 mg in Korean participants using it in real-world conditions. The study focuses on monitoring serious and non-serious adverse events and drug reactions, including unexpected ones, as well as changes in disease activity scores related to rheumatoid arthritis and ulcerative colitis. Participants prescribed Jyseleca according to Korean approved therapeutic indications will be observed without additional intervention. They will be followed for up to 24 weeks or until they stop treatment due to adverse events or other reasons. The study includes adults with rheumatoid arthritis or ulcerative colitis who have not responded well or are intolerant to prior treatments. During the study, researchers will track adverse events and reactions from enrollment through 24 weeks. They will also measure changes in disease activity scores at baseline, week 12, and week 24. Participants will have regular monitoring visits as part of their usual care, with data collected about safety and treatment effects. The total participation time is up to 24 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT in adults aged 55 to 90 years with mild to severe Alzheimers Disease that includes moderate to severe psychosis symptoms. This Phase 3 study focuses on treating psychosis related to Alzheimers Disease using a randomized, double-blind, placebo-controlled design. Participants receive either KarXT or a placebo at specified doses on scheduled days. The study lasts up to 14 weeks, during which the impact of KarXT on hallucinations, delusions, and other neuropsychiatric symptoms is assessed. The research also monitors various safety measures and cognitive function throughout this period. During the study, participants undergo evaluations including neuropsychiatric inventories, clinical global impression scales, cognitive tests like the Mini-Mental State Examination and Alzheimers Disease Assessment Scale, as well as safety monitoring through laboratory tests, vital signs, ECGs, and assessments for adverse events. The primary outcome is the change in hallucinations and delusions score up to week 14, with ongoing safety and efficacy assessments throughout the treatment period.
Actively Recruiting
Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.
Actively Recruiting
Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.
Actively Recruiting
Researchers are evaluating the effects of aspirin and high-intensity statin therapy in people with severe coronary calcification, defined as a coronary calcium score of 300 or higher. The trial aims to understand how these treatments may help prevent atherosclerotic cardiovascular disease ASCVD events in this population. This phase 4, randomized, open-label trial uses a factorial design to assess both aspirin use and statin intensity. Participants are assigned to one of four groups aspirin 100 mgday with high-intensity statin therapy no aspirin with high-intensity statin therapy no aspirin with guideline-directed statin therapy or aspirin 100 mgday with guideline-directed statin therapy. Statin intensity follows the 2026 ACCAHA Guideline on the Management of Dyslipidemia. The study treatment lasts for 3 years, during which participants take the assigned medications. Throughout the trial, participants will be monitored for cardiovascular events and safety outcomes over 3 years. The main outcome is the rate of a composite of ASCVD events. Secondary outcomes include rates of individual cardiovascular events, death from any cause, hospitalization for heart failure, major bleeding, and safety endpoints. Participants will provide informed consent and follow the study protocol with scheduled clinical follow-ups to assess these outcomes.
Actively Recruiting
Researchers are evaluating the effect of low-dose aspirin 100 mg daily on preventing gastric cancer in patients with early gastric cancer or high-grade adenoma who have undergone endoscopic resection and have a negative or eradicated Helicobacter pylori status. This randomized, placebo-controlled Phase 3 trial addresses limitations in previous studies by focusing specifically on gastric cancer prevention with appropriate sample size and follow-up. Aspirin is commonly used to reduce cardiovascular risks, and some evidence suggests it may also lower gastrointestinal cancer risk, but more targeted research is needed. Participants will be randomly assigned to receive either enteric-coated aspirin 100 mg daily or a placebo tablet for five years. This double-blind study compares the incidence of gastric cancer between the aspirin and placebo groups. The trial includes a treatment period of five years, during which participants take the assigned medication daily. The study also monitors secondary outcomes like mortality, cardiovascular events, occurrence of other cancers, gastric dysplasia, aspirin-related complications, and gastric tissue improvements. During the study, participants will undergo regular assessments including pathology reviews after endoscopic resection and monitoring for adverse events. Researchers will track the primary outcome of gastric cancer incidence throughout the treatment period. Secondary outcomes such as cardiovascular disease rates and overall survival will also be evaluated. The total participant involvement includes screening, a five-year medication period, and ongoing monitoring to assess treatment effects and safety.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Breztri in real-world clinical practice among patients diagnosed with Chronic Obstructive Pulmonary Disease COPD or asthma in Korea. This open-label, single-arm, multicenter observational study aims to confirm known safety outcomes and identify any new adverse drug reactions. It also seeks to generate clinical evidence from a diverse group of Korean patients representative of everyday medical care. Patients who start treatment with Breztri following approved indications in Korea will be enrolled and observed for up to 24 weeks. The study allows physicians to prescribe other necessary medications as part of routine care. Patient visits and follow-up schedules are determined based on clinical need, with approximately 600 patients expected across about 30 study sites. Participants will be monitored for adverse events, serious adverse events, and unexpected reactions during the 24-week period or until treatment ends if discontinued earlier. Clinical outcomes will be assessed at baseline, 12 weeks, and 24 weeks, including changes in COPD Assessment Test scores. Researchers will also explore patient baseline factors related to safety and outcomes. No additional follow-up occurs if exclusion criteria appear after enrollment.
Actively Recruiting
Researchers are evaluating the diagnostic performance and clinical impact of coronary angiography and intravascular ultrasound IVUS-based machine learning ML models in patients with coronary artery disease undergoing percutaneous coronary intervention PCI. This multicenter, prospective study aims to validate these AI-driven tools for decision making and stent optimization by assessing their prognostic effects on treated and deferred coronary lesions. The study will enroll 3,000 patients from 16 centers between January 2020 and June 2027. Participants will undergo coronary angiography with or without fractional flow reserve FFR measurement and IVUS imaging. The study evaluates ML algorithms including angiography- and IVUS-based models predicting FFR, plaque characterization, stent expansion, and post-stenting stent failure. The trial focuses on two primary objectives the impact of the integrated ML model on 2-year target vessel failure TVF related to treated culprit lesions and deferred nonculprit lesions. During the study, researchers will monitor participants over two years after stent implantation to measure outcomes such as culprit- and nonculprit-related TVF. Additional outcomes include death from any cause, repeat revascularization, stroke, and bleeding events. Data from coronary imaging, clinical evaluations, and follow-up visits will be collected to assess the clinical value of the AI models and their influence on patient outcomes.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Cellgram-LC, a biological treatment involving a single injection of autologous bone marrow-derived mesenchymal stem cells, in patients with alcoholic cirrhosis. This randomized, open-label Phase III trial compares Cellgram-LC with best supportive care BSC to determine if Cellgram-LC improves transplant-free survival and to identify any medical problems following treatment. Participants are assigned to one of two groups one group receives a single dose of Cellgram-LC through the hepatic artery at Week 0, and the other receives best supportive care. The study uses a parallel design with random allocation to these groups. Assessments occur at scheduled clinic visits at Week 4 and Months 3, 6, 9, 12, 18, and 24, along with telephone follow-ups at various months up to Month 36. During the study, participants undergo regular evaluations including liver function tests, fibrosis assessments, and quality of life questionnaires. Researchers measure transplant-free survival over three years as the primary outcome, along with survival rates, scores assessing liver function and fibrosis, and health status changes. The trial includes ongoing monitoring through clinic visits and telephone contacts, with total participation lasting up to 36 months.
1-10 of 33
1